Published in Genet Epidemiol on February 01, 2000
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet (2001) 5.08
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer (2000) 4.37
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer (2002) 4.18
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol (2006) 3.73
Variation of breast cancer risk among BRCA1/2 carriers. JAMA (2008) 3.30
Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet (2011) 3.25
BayesMendel: an R environment for Mendelian risk prediction. Stat Appl Genet Mol Biol (2004) 2.34
Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proc Natl Acad Sci U S A (2006) 1.99
Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med (2007) 1.94
Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol (2010) 1.89
BRCA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet (2002) 1.80
Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol (2009) 1.61
Occupational exposure to asbestos and ovarian cancer: a meta-analysis. Environ Health Perspect (2011) 1.51
MYC in breast tumor progression. Expert Rev Anticancer Ther (2008) 1.49
Sibling risks in cancer: clues to recessive or X-linked genes? Br J Cancer (2001) 1.44
Clinical significance of large rearrangements in BRCA1 and BRCA2. Cancer (2012) 1.11
Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. PLoS One (2007) 1.08
Population prevalence of hereditary breast cancer phenotypes and implementation of a genetic cancer risk assessment program in southern Brazil. Genet Mol Biol (2009) 1.08
Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. Cancer Res (2010) 1.08
A novel BRCA2 mutation in an Indonesian family found with a new, rapid, and sensitive mutation detection method based on pooled denaturing gradient gel electrophoresis and targeted sequencing. J Clin Pathol (2005) 1.08
Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Res (2003) 1.03
Hereditary ovarian cancer in Ashkenazi Jews. Fam Cancer (2004) 0.91
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol (2012) 0.91
c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells. BMC Cancer (2011) 0.83
The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. Med J Islam Repub Iran (2016) 0.83
The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2009) 0.82
A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. J Med Genet (2015) 0.82
BRCA1 and BRCA2 mutations in Iranian breast cancer patients: A systematic review. J Res Med Sci (2015) 0.81
No sib pair concordance for breast or ovarian cancer in BRCA1 mutation carriers. Hered Cancer Clin Pract (2007) 0.78
Cancer genetics: risks and mechanisms of cancer in women with inherited susceptibility to epithelial ovarian cancer. Cancer Treat Res (2010) 0.76
Recognizing BRCA gene mutation risk subsequent to breast cancer diagnosis in southwestern Ontario. Can Fam Physician (2012) 0.76
Effect of lifestyle and reproductive factors on the onset of breast cancer in female BRCA 1 and 2 mutation carriers. Mol Genet Genomic Med (2015) 0.76
Epithelial ovarian cancer. Risk factors, screening and the role of prophylactic oophorectomy. Hippokratia (2007) 0.75
Complex segregation analysis of pedigrees from the Gilda Radner Familial Ovarian Cancer Registry reveals evidence for mendelian dominant inheritance. PLoS One (2009) 0.75
Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers. J Clin Oncol (2015) 0.75
The Activities and Impact of State Programs to Address Hereditary Breast and Ovarian Cancer, 2011-2014. Healthcare (Basel) (2015) 0.75
A recessive Mendelian model to predict carrier probabilities of DFNB1 for nonsyndromic deafness. Hum Mutat (2006) 0.75
Identification and management of women with a family history of breast cancer: Practical guide for clinicians. Can Fam Physician (2016) 0.75
Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer. Cancer Epidemiol Biomarkers Prev (2011) 0.75
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994) 9.60
Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. Genomics (1992) 9.06
Survival of patients with breast cancer attending Bristol Cancer Help Centre. Lancet (1990) 7.04
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst (1999) 6.48
Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst (1994) 6.27
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet (2005) 6.18
Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab (2001) 6.12
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet (1995) 4.86
Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer (1997) 4.47
Involvement of Brca2 in DNA repair. Mol Cell (1998) 4.41
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer (2002) 4.18
Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet (1997) 4.16
The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer (2004) 4.06
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 3.81
Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet (1995) 3.71
Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med (1998) 3.60
Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet (1996) 3.53
Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol (2001) 3.35
A clonal marker induced by mutation in mouse intestinal epithelium. Nature (1988) 3.35
Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature (1994) 3.33
Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev (1999) 3.29
Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet (1992) 3.13
How many more breast cancer predisposition genes are there? Breast Cancer Res (1999) 3.10
Cytogenetic analysis by chromosome painting using DOP-PCR amplified flow-sorted chromosomes. Genes Chromosomes Cancer (1992) 3.03
Development of the pattern of cell renewal in the crypt-villus unit of chimaeric mouse small intestine. Development (1988) 2.97
Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene (1995) 2.91
Mutations truncating the EP300 acetylase in human cancers. Nat Genet (2000) 2.84
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet (2008) 2.81
An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet (1993) 2.79
Models of genetic susceptibility to breast cancer. Oncogene (2006) 2.69
DNA "fingerprints" and segregation analysis of multiple markers in human pedigrees. Am J Hum Genet (1986) 2.55
Familial breast cancer. BMJ (1994) 2.54
Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet (1997) 2.53
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet (2001) 2.50
Instability of short tandem repeats (microsatellites) in human cancers. Nat Genet (1994) 2.45
High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res (1996) 2.43
A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev (1999) 2.39
Familial gastric cancer: overview and guidelines for management. J Med Genet (1999) 2.38
Derivation of mouse intestinal crypts from single progenitor cells. Nature (1985) 2.31
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer (2011) 2.28
Deletion of genes on chromosome 1 in endocrine neoplasia. Nature (1987) 2.27
Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet (2000) 2.26
Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res (1998) 2.20
A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature (1987) 2.15
ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet (1998) 2.06
The extent of linkage disequilibrium in four populations with distinct demographic histories. Am J Hum Genet (2000) 2.03
The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. Oncogene (1989) 2.02
Cell migration pathway in the intestinal epithelium: an in situ marker system using mouse aggregation chimeras. Cell (1985) 2.02
Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology (2006) 1.98
A polymorphic stop codon in BRCA2. Nat Genet (1996) 1.95
Stem-cell organization in mouse small intestine. Proc Biol Sci (1990) 1.93
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA (1995) 1.83
A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet (2000) 1.80
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet (1996) 1.79
The genetics of breast and ovarian cancer. Br J Cancer (1995) 1.78
Apolipoprotein E genetic variation and Alzheimer's disease. a meta-analysis. Dement Geriatr Cogn Disord (1999) 1.73
Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol (1997) 1.73
Rapid detection of regionally clustered germ-line BRCA1 mutations by multiplex heteroduplex analysis. UKCCCR Familial Ovarian Cancer Study Group. Am J Hum Genet (1996) 1.72
Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet (1994) 1.71
A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol (1998) 1.70
The arrangement of nucleosomes in nucleoprotein complexes from polyoma virus and SV40. Cell (1977) 1.69
CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst (2000) 1.69
Presymptomatic screening for multiple endocrine neoplasia type 2A with linked DNA markers. The MEN 2A International Collaborative Group. Lancet (1991) 1.68
Paternal origin of new mutations in von Recklinghausen neurofibromatosis. Nature (1990) 1.64
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res (2000) 1.62
Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia. Am J Hum Genet (1997) 1.62
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet (1998) 1.61
Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol (2007) 1.61
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int (2010) 1.60
Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet (1997) 1.55
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer (2009) 1.54
Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol Cell (1999) 1.53
Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res (1999) 1.51
Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. Magn Reson Imaging (2000) 1.47
Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res (1996) 1.47
A low proportion of BRCA2 mutations in Finnish breast cancer families. Am J Hum Genet (1997) 1.46
The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. Am J Hum Genet (1999) 1.45